Vivalyx
The company develops Omnisol, a patented blood-free liquid solution designed to preserve and revitalize donor organs for transplantation. This solution is compatible with multiple preservation methods including static cold storage and machine perfusion, aiming to increase the number and viability of organs available for patients on waiting lists. Their technology serves the medical transplant industry by reducing complication rates and eliminating the need for blood-based perfusates.
Visit websiteCologne, Germany
Healthtech
MedTech
Biotechnology
Funding summary
- Total raised
- €13.9M
- Funding rounds
- 3
Investors in Vivalyx
Investors on record for Vivalyx. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Vivalyx?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors